Researchers at Queen Mary University of London introduced Ovatools, a personalized diagnostic instrument combining biochemical markers with demographic data for improved ovarian cancer risk assessment. This innovation aims to enhance early detection in primary care settings, potentially transforming patient outcomes by enabling timely interventions. The validated tool addresses a critical need as ovarian cancer remains difficult to detect at early stages using conventional methods.